Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
D Charles, J Shanley, SN Temple… - Clinical & …, 2022 - Wiley Online Library
Background Severe asthma is a major cause of morbidity. Some patients may benefit from
biological therapies. Most evaluations of these treatments are derived from randomized …
biological therapies. Most evaluations of these treatments are derived from randomized …
Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives
Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …
Targeting TSLP in asthma
JR Parnes, NA Molfino, G Colice, U Martin… - Journal of asthma …, 2022 - Taylor & Francis
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the
initiation and persistence of inflammatory pathways in asthma. Released in response to a …
initiation and persistence of inflammatory pathways in asthma. Released in response to a …
[HTML][HTML] Effective management of severe asthma with biologic medications in adult patients: a literature review and international expert opinion
Severe asthma often remains uncontrolled despite effective treatments and evidence-based
guidelines. A group of global experts in asthma and biologic medications from 9 countries …
guidelines. A group of global experts in asthma and biologic medications from 9 countries …
Specific therapy for T2 asthma
D Bagnasco, E Testino, S Nicola, L Melissari… - Journal of Personalized …, 2022 - mdpi.com
Asthma is a disease with high incidence and prevalence, and its severe form accounts for
approximately 10% of asthmatics. Over the last decade, the increasing knowledge of the …
approximately 10% of asthmatics. Over the last decade, the increasing knowledge of the …
Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta-analysis
Z Zoumot, N Al Busaidi, W Tashkandi… - Journal of Asthma …, 2022 - Taylor & Francis
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an
epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. It was approved by …
epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. It was approved by …
Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy
W Chen, M Sadatsafavi, TN Tran… - Journal of asthma …, 2022 - Taylor & Francis
Background Many severe asthma patients with high oral corticosteroid exposure (HOCS)
often do not initiate biologics despite being eligible. This study aimed to compare the …
often do not initiate biologics despite being eligible. This study aimed to compare the …
Using a knowledge translation framework to identify health care professionals' perceived barriers and enablers for personalised severe asthma care
EC Majellano, VL Clark, RF McLoughlin, PG Gibson… - Plos one, 2022 - journals.plos.org
Background Whilst multidimensional assessment enables the detection of treatable traits in
severe asthma and has the potential to improve patient outcomes, healthcare disparities …
severe asthma and has the potential to improve patient outcomes, healthcare disparities …
[HTML][HTML] Gulf asthma diagnosis and management in adults: expert review and recommendations
N Al Busaidi, A Alweqayyan, A Al Zaabi… - The Open Respiratory …, 2022 - ncbi.nlm.nih.gov
The prevalence and incidence of asthma are increasing globally because of genetic and
environmental influences. Prevalence of asthma in the Gulf has been reported to range from …
environmental influences. Prevalence of asthma in the Gulf has been reported to range from …
Clinical and lung function outcomes after anti-IgE or anti-IL5 therapy in severe asthma
S AlShareef, CF McDonald, J Lee - Journal of Asthma and Allergy, 2022 - Taylor & Francis
Background Although there have been indirect comparisons of the relative efficacy of
mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in severe asthma patients, long …
mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in severe asthma patients, long …